Skip to main content
. 2016 Sep 9;175(3):393–401. doi: 10.1111/bjh.14270

Figure 1.

Figure 1

CLEC12A expression on the CD34+ CD38− stem cell subset. (A) Gating strategy (MDS Patient 9). In the first panel, the CD45low/SSClow population was defined. Next, the CD34+ CD38− population was gated and analysed for the presence/absence of CLEC12A. The last panel shows the CD34+ CD38− CLEC12A+ population back‐gated into the CD34+ CD38− plot. (B) CLEC12A expression on the CD34+ CD38− cell subset in normal bone marrow (NBM), myelodysplastic syndrome (MDS), CD34‐positive (CD34+) acute myeloid leukaemia (AML) and CD34‐negative (CD34−) AML, respectively. (C) CLEC12A expression on the CD34+ CD38− cell subset according to IPSS‐R risk groups. Filled symbols indicate later progression to AML.